COVID-19 Update - This is to inform you that the Government of India has announced a complete lockdown in India 22nd March 2020 to 14th April 2020. As a result, our offices will now be closed till 14th April 2020 and all our employees will be working from home. Office telephones will not be answered, and therefore you are requested to direct all your queries related to manuscript submission, review process, publication etc. at below mentioned details.,, Mob. 8826373757, 8826859373, 9910947804

Article view: 513

Article download: 231

Indian Journal of Pharmacy and Pharmacology

Study of serum glucose and cholesterol level in schizophrenic patient’s before and after treatment of olanzapine, risperidone and haloperidol

Full Text PDF Share on Facebook Share on Twitter

Author Details : Ajay Kumar Halwai, Vinod Koshley*, Rajesh Hishikar, Basant Maheshwari, Usha Joshi

Volume : 5, Issue : 3, Year : 2018

Article Page : 146-152

Suggest article by email


Objectives: To evaluate the potential association between antipsychotics (Olanzapine, Risperidone and Haloperidol), serum glucose level and serum cholesterol level in schizophrenic patients.
Introduction: Schizophrenia is quite prevalent and has high rate of chronicity and morbidity. Newer atypical antipsychotic drugs were developed in response to limitations such as lack of efficacy and side effects associated with older (conventional) agents. However, significant hyperglycemia, dyslipidemia and weight gain have been reported with the use of newer atypical antipsychotics.
Materials and Methods: This was an observational prospective study. Total 75 schizophrenic patients were divided in three groups according to treatment allocated (group I- olanzapine, group II- risperidone, group III haloperidol) comprising of 25 patients in each group. Blood sample was collected when patient came to hospital for the first time before starting the treatment and 6 weeks after treatment, then again 6 months after treatment, fasting serum glucose and cholesterol levels were estimated by enzymatic procedure. Simultaneously body weight was also measured.
Results: In this study majority of patients were male-73.33% with mean age of 30.76 years. There were significant increase in serum glucose levels and serum cholesterol level, after 6 weeks and 6 months of treatment (t=3.11 p<0 xss=removed xss=removed> t=3.65 p < 0 t=3.11,> Conclusion: Olanzapine was associated with increased risk of glucose intolerance, dyslipidemia and weight gain.

Keywords: Antipsychotics, Schizophrenia, Cholesterol, Diabetes, Weight gain.

Doi : 10.18231/2393-9087.2018.0031

How to cite : Halwai A K, Koshley V, Hishikar R, Maheshwari B, Joshi U, Study of serum glucose and cholesterol level in schizophrenic patient’s before and after treatment of olanzapine, risperidone and haloperidol. Indian J Pharm Pharmacol 2018;5(3):146-152

Copyright © 2018 by author(s) and Indian J Pharm Pharmacol. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0) (